Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953414 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL812418 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998727 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996449 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL4628774 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2991651 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996446 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998728 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL943172 | 0.94 | MEN1 (0.39) | CHRNB2CHRNA7CHRNA4L3MBTL1PARP1 | |
| Proline SCHEMBL28261914 | 0.86 | GRIN2D (0.35) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111494395-B | Carbidopa and levodopa prodrugs and their use for treating parkinson's disease | 艾伯维公司 | 2024-06-21 | — | — | CN | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230106081-A1 | METHODS OF TREATING PARKINSON'S DISEASE | ABBVIE INC. | 2023-04-06 | — | — | US | disclosed |
| EP-3421454-B1 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-04-05 | — | — | EP | disclosed |
| CN-108884044-B | Piperidine derivatives | 大塚制药株式会社 | 2023-01-31 | — | — | CN | disclosed |
| CN-111454290-B | Carbidopa and levodopa prodrugs and their use for treating parkinson's disease | 艾伯维公司 | 2022-12-23 | — | — | CN | disclosed |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | The State of Oregon acting by and through the State Board of Higher Education on behalf of Orego | 2010-07-22 | — | — | US | disclosed |
| WO-2009039181-A2 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OR. STATE UNIV. (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039181-A2 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | STATE OF OREGON ACTING BY & THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OR. STATE UNIV. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200687-A1 | Preparation of Terazole Derivatives | TERB1, TALDO1, TERT | CHRNB2 3403/4885CHRNA7 1808/4885CHRNA4 2558/4885 |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | TERB1, TALDO1, TERT | CHRNB2 3403/4885CHRNA7 1808/4885CHRNA4 2558/4885 |
| US-20230106081-A1 | METHODS OF TREATING PARKINSON'S DISEASE | SNCA, PARK7, COMT | CHRNB2 110/4885CHRNA7 221/4885CHRNA4 177/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | CHRNB2 172/4885CHRNA7 221/4885CHRNA4 174/4885 |
| US-20100184986-A1 | SULFONAMIDE-BASED ORGANOCATALYSTS AND METHOD FOR THEIR USE | ALDH7A1, SULT1A1, SULT2A1 | CHRNB2 3706/4885CHRNA7 3974/4885CHRNA4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.